Welcome to our dedicated page for Biohaven SEC filings (Ticker: BHVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biohaven Ltd.'s SEC filings document the formal disclosures of a British Virgin Islands clinical-stage biopharmaceutical company listed under BHVN. The filing record includes Form 8-K reports for operating results, Regulation FD presentations, clinical and regulatory pipeline updates, and material equity financing events involving common shares.
Proxy and annual-meeting filings cover director elections, auditor ratification, executive compensation votes and shareholder governance matters. Registration-related disclosures and prospectus supplements describe shelf registration mechanics, at-the-market equity distribution arrangements, underwriting agreements and common-share issuance activity that support the company's development-stage funding strategy.
Biohaven Ltd. Chief Scientific Officer Bruce Car received a grant of stock options on February 27, 2026. The award covers 175,000 stock options with an exercise price of $0.00 per share, giving him the right to buy Biohaven shares if he chooses to exercise in the future.
The options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, and each installment requires his continuous service with the company through the relevant vesting date. After this grant, he directly holds 175,000 derivative securities in the form of stock options.
Coric Vlad reported acquisition or exercise transactions in this Form 4 filing.
Biohaven Ltd. Chief Executive Officer Vlad Coric reported receiving a grant of stock options on February 27, 2026. The award covers 550,000 stock options with a stated price per share of $0.00, increasing his directly held option position to 550,000 derivative securities.
According to the footnote, the options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, and each vesting is conditioned on his continuous service with Biohaven on the relevant vesting date.
Biohaven Ltd. reported another year of heavy investment in its pipeline, posting a 2025 net loss of $738.8M, or $6.86 per share, compared with a $846.4M loss in 2024. Research and development expenses were $635.1M, down from $795.9M, reflecting prior one-time costs and a shift toward three late-stage programs in immunology, epilepsy and obesity.
Cash, cash equivalents, marketable securities and restricted cash totaled about $322.0M as of December 31, 2025. After year-end, Biohaven raised net proceeds of $178.9M by issuing 17.2 million common shares and had previously completed a roughly $200M 2025 equity offering and an Oberland Capital financing of up to $600M.
The company highlighted strong early clinical signals from its MoDE™ and TRAP™ degrader platform (BHV‑1300 for Graves’ disease and BHV‑1400 for IgA nephropathy), its Kv7 ion channel activator opakalim for focal epilepsy, and myostatin‑activin inhibitor taldefgrobep for obesity, with multiple pivotal and Phase 2/3 readouts expected in the second half of 2026.
Biohaven Ltd. is a biopharmaceutical company focused on immunology, neuroscience, and oncology, highlighting a shift toward three late-stage “key programs.” These include the IgG degrader BHV-1300 for Graves’ disease and other autoimmune conditions, the TRAP degrader BHV-1400 for IgA nephropathy, and the Kv7 activator opakalim for epilepsy.
The report describes strong Phase 1 data for BHV-1300 and BHV-1400 and plans to start pivotal trials for Graves’ disease and IgA nephropathy in 2026. It also outlines the myostatin inhibitor taldefgrobep alfa in obesity and spinal muscular atrophy, and extensive work on the glutamate modulator troriluzole in spinocerebellar ataxia. However, the FDA issued a Complete Response Letter for the SCA New Drug Application, taldefgrobep did not meet the primary endpoint in spinal muscular atrophy, and opakalim failed primary endpoints in major depressive disorder and bipolar disorder, underscoring regulatory and clinical risk.
Suvretta Capital Management and affiliates reported significant ownership stakes in Biohaven Ltd. common shares as of 12/31/2025. Suvretta Capital Management, LLC and its principal, Aaron Cowen, each beneficially own 10,286,937 common shares, representing 7.8% of the class, with shared voting and dispositive power over these shares.
Averill Master Fund, Ltd., an advisory client of Suvretta, directly owns 8,800,438 common shares, equal to 6.6% of the class, also with shared voting and dispositive power. All securities in this amendment are directly owned by Suvretta advisory clients, and the reporting persons state that the holdings are not for the purpose of changing or influencing control of Biohaven.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 16,803,459 common shares of Biohaven Ltd., representing 12.7% of the class as of the triggering event on 01/30/2026.
The shares are held across multiple investment advisers and their client accounts, referred to as Managed Portfolios. Janus Henderson’s asset managers share voting and investment power over these Biohaven shares, while the Managed Portfolios themselves receive all dividends and sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Biohaven.
Biohaven Ltd. disclosed that it will be making an investor presentation on January 12, 2026. The company has prepared an investor slide deck, described as an Investor Presentation dated January 2026, and made it available as an exhibit to this report so that the broader market has access to the same information shared with investors.
The presentation materials are furnished for informational purposes only under Regulation FD, meaning they are not treated as formally filed financial statements or incorporated into other securities law documents unless specifically referenced in the future.
Biohaven Ltd. senior vice president of clinical operations Kimberly Gentile reported routine equity transactions tied to restricted share units. On January 5, 2026, 3,750 restricted share units converted into the same number of common shares at an exercise price of $0, increasing her directly held stake. To cover tax withholding on this vesting, 1,956 common shares were withheld by the company at a price of $9.93 per share, with no shares sold into the market. After these transactions, Gentile directly owned 99,557 common shares and held 7,500 restricted share units, which represent the right to receive additional common shares as future vesting dates are met.
Biohaven Ltd. Chief Financial Officer Matthew Buten reported equity award activity and related tax withholding on common shares. On January 5, 2026, 4,250 restricted share units were exercised at an effective price of $0, delivering the same number of common shares. To cover taxes due on this vesting, 2,594 common shares were withheld by Biohaven at a price of $9.93 per share, and no shares were sold into the market.
After these transactions, Buten directly beneficially owned 195,652 common shares, which includes 544 shares acquired through the Biohaven Employee Share Purchase Plan on May 31, 2025. He also held 8,500 restricted share units following the reported transaction, each representing the right to receive one common share, with the original 17,000-unit grant vesting in four annual installments through January 5, 2028, subject to continued service.
Biohaven Ltd. Chief Executive Officer and director Vlad Coric reported routine equity compensation activity. On January 5, 2026, 14,250 restricted share units vested and were converted into 14,250 common shares at $0 per share. On the same date, 7,430 common shares were withheld by Biohaven at $9.93 per share to cover tax obligations, and no shares were sold into the market.
Following these transactions, Coric directly holds 1,803,968 common shares and 28,500 restricted share units. Additional common shares are held indirectly through a family trust, a marital trust and a 401(k) plan. The family and marital trust positions are for the benefit of family members other than Coric, and he disclaims beneficial ownership of those securities.